



Impact of SARS-Cov-2 on Clinical Trial Unit Workforce in the United Kingdom: An Observational Study

Gayathri Delanerolle¹, Jintong Hu², Heitor Cavalini³, Katharine Barnard-Kelly³, Kathryn Elliot³, Vanessa Raymont⁴, Shanaya Rathod⁵, Jian Qing Shi^{2,3,6} and Peter Phiri^{5*}

¹Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

²Southern University of Science and Technology, Shenzhen, 518055, China

³Research & Innovation Department, Southern Health NHS Foundation Trust, SO40 2RZ, UK

⁴Department of Psychiatry, University of Oxford, OX3 7JX, Oxford, UK

⁵Psychology Department, Faculty of Environmental and Life Sciences, University of Southampton, SO17 1BJ, Southampton, UK

⁶The Alan Turing Institute, NW1 2DB, London, UK

*Corresponding author: Peter Phiri, Research & Innovation Department, Southern Health NHS, Foundation Trust, Clinical Trials Facility, Tom Rudd Unit Moorgreen Hospital, United Kingdom

Received: 📅 August 4, 2023

Published: 📅 August 17, 2023

Abstract

Background: The overall objective of this mixed-method digital-based observational study was to determine the mental health impact among CTU staff working during the COVID-19 pandemic.

Methods: The Qualtrics Core XM platform was used to deploy the questionnaire where a quantitative analysis was conducted. The qualitative part of the study used the Microsoft Teams digital application to complete the interviews. Various validated mental health assessments were administered: Vancouver Index of Acculturation (VIA), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), Pandemic Stress Index (PSI), Burnout Assessment Tool-12 (BAT-12), General Self Efficacy Scale (GSE) and The Everyday Discrimination Scale (EDS).

Result: A total of 485 participants took part, of which 73.4% were female and 70.1% of the sample were white British. A high prevalence of anxiety, exhaustion and depression were identified across all participants.

Conclusion: A significant mental health impact was identified among the CTU workforce where wellbeing was compromised during the course of the COVID-19 pandemic.

Keywords: COVID-19; Clinical Trials; Mental Health; Vaccination; CTU workforce

Introduction

The World Health Organization (WHO) declared the outbreak of the COVID-19 pandemic on 11th of March 2020 which impacted the clinical research workforce significantly [1]. Lockdown, face masks, social distancing and various other measures were used to manage the spread of the virus [2]. While much of the spotlight was on incidence and prevalence of COVID-19, the impact on conduct

ing scientific research was significant. Existing clinical trials were paused especially within the UK and COVID-19 research was prioritised [3,4]. In the UK, the clinical trial profession as a whole has a number of staffing groups with a variety of job titles. Industry, academia, and the NHS struggle to recruit and retain clinical trial staff. As of Nov 2022, Indeed indicated almost 3,500 unfilled clinical

trial positions nationally [5]. Whilst this could be due to a variety of reasons including short term contracts, workload acumen, issues with salaries for the expected job specification, and lack of flexibility for hybrid working, a higher vacancy rate impacts on the existing clinical trial workforce as they would be required to cover a larger volume of work.

According to the National Institute for Health Research (NIHR), new clinical trials, even for complex and urgent areas such as cancer, were suspended in the UK, and staff were redeployed [6,7]. Clinical Trials Units (CTUs) are specialist units that play a key role in study design, conduct, analysis, and subsequent publication. CTUs house expert clinical research staff, including clinical trialists, statisticians, epidemiologists, methodologists, quality assurance and trial management staff that have experience to setup, manage and deliver clinical trials. Some CTUs deliver a diverse array of studies, whilst others specialise in either a specific clinical area or a type of intervention such as investigational medicinal products, medical devices and complex interventions. CTUs are legally responsible for maintaining adherence to all compliance procedures regardless of their embodiment within an academic or NHS organisation. The CTUs played an essential role during the pandemic in the UK. The Management of Health and Safety at Work Regulations (1999 as amended) requires employers to ensure the work environment is, as far as reasonably practicable, safe and without risks to health. The COVID-19 pandemic introduced an unforeseen risk that had not been considered previously.

Some countries have reported challenges to manage their research during the pandemic, facing challenges that include physical violence perpetrated towards members of the medical staff, unreliable therapies, and prejudice amongst ethnic minorities health workers in frontlines against the virus [4,8,9]. However, the impact on the CTU workforce has not been explored. Hence, this study explores the COVID-19 impact with an aim to report the challenges and develop strategies to better develop pandemic frameworks in the future.

Materials and Methods

The CTU workforce in the UK is approximated around 25,000 although some staff have shared roles with multiple departments spanning across academic and NHS organisations. We designed a mixed methods observational-digital study to explore the experiences of CTU staff within the UK. The survey was deployed digitally

via the NIHR, UKTMN, social media and the UK CRC.

Aims

The primary aim of the study was to determine the mental health impact due to the challenges faced by the clinical trial workforce whilst delivering clinical research during the COVID-19 pandemic. The secondary aim of the study was to determine the impact on staff wellbeing that would aid to propose a suitable pandemic preparedness framework for clinical trial units and staff conducting studies during a pandemic.

Eligibility Criteria

All participants that were 18 years and above, employed within a CTU in the UK were eligible to participate in the study. Participants also required to have access to a smartphone, tablet, or computer to complete the survey online, and willing to provide informed e-consent.

Data Collection and Extraction

Quantitative data was collected through an online questionnaire using the Qualtrics Core XM platform. The sample size comprised of 485 participants. A random subgroup of the sample was invited to take part in semi-structured interviews. All interviews were conducted via a secure online facility (password protected teams teleconference), audio-recorded and transcribed in full. Data collection and analysis were integrated with a process based on framework methodology used to analyse the data including development of a coding frame based on identified key themes and detailed coding of transcripts.

Outcome Measures

Quantitative measures were used to evaluate mental health impact byway of validated questionnaires. For the purpose of this study, we used Vancouver Index of Acculturation (VIA), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), Pandemic Stress Index (PSI), Burnout Assessment Too-12 (BAT-12), General Self Efficacy Scale (GSE) and The Everyday Discrimination Scale (EDS). Table 1 displays the summary of validated questionnaires including cut-off scores, construct of questionnaires, analytic rationale, and dimensions. Cut-off scores were used to ensure the erroneous decisions for each mental health assessment completed by all study participants could be unified for the purpose of the analysis.

Table 1: Summary of validated questionnaires.

Questionnaire	Cut-off scores	Construct	Analytic Rationale	Dimensions
Demographic information	None	Equity issues	Moderator	One dimension
Hospital Anxiety and Depression Scale (HADS)	A total score of 11 or higher indicates the probable presence of the mood disorders, with a score of 8 to 10 being just suggestive of the presence of the respective state.	Psychological impact - Anxiety & Depression	Outcome measure	Anxiety score (odd items) Depression score (even items)
General Self-Efficacy (GSE)	None	Assessment of general self-efficacy	Moderator	One dimension
Pandemic Stress Index (PSI)	None	Psychological impact	Outcome measure	One dimension
Insomnia Severity Index (ISI)	A score of: 0-7 is indicative of no insomnia; 8-14 indicative of a subthreshold insomnia; 15-21 moderate insomnia; 22-28 is indicative of severe insomnia.	Psychological impact - Sleep Quality	Outcome measure	One dimension
Vancouver Index of Acculturation (VIA)	None	Disadvantages and equity issues - cultural context	Moderator or mediator	Heritage score Mainstream score
Burnout Assessment Tool (BAT-12)	None	Psychological impact	Moderator	Exhaustion score Mental distance score Cognitive impairment score Emotional score impairment
The Everyday Discrimination Scale (EDS)	None	Workplace and occupational	Moderator or mediator	One dimension
AHRQ Patient safety culture survey	None	Workforce and occupational	Moderator or mediator	One dimension

Analysis Plan

Quantitative

The analysis focused on 9 questionnaires with 14 dimensions. Participants were divided into several subgroups based on age, gender, ethnicity, role, and length of service. Mean and standard deviation scores on 14 dimensions were calculated. ANOVA and t-tests were applied to check the difference in means between different subgroups. A correlation heat-map was used to demonstrate the correlation between each questionnaire based on Spearman correlation. An item-total correlation was calculated to focus on the core items. Total item correlation in this instance refers to the correlation coefficient summarised between each specific item and other items, which is the quantification of the importance of specific item. Linear regression was used to investigate the mental health impact during the pandemic.

Qualitative

Transcripts were analysed using thematic and content analysis. Two experienced qualitative researchers independently reviewed transcripts and conduct analyses. A coding framework was developed to capture key themes with each coded theme subjected to detailed analyses to identify subthemes and illustrative quotes.

Results

Quantitative

A sample of 485 staff members completed the questionnaire, as outlined in Figure 1. Key characteristics of the sample are indicated in Table 2 including all sexes, ages, and geographies. 257 participants did not disclose their professional category and job title, whilst 60 and 228 participants reported these, respectively (Figure 1).

Table 2: Demographic Characteristics of the Sample (n = 485).

Demographics of Trail Management Participants (N = 127)		
Variables		N (%)
Age	18-24	1 (0.8%)
	25-34	23 (18.1%)
	35-44	46 (36.2%)
	45-54	35 (27.6%)
	55-64	17 (13.4%)
	65 and over	5 (3.9%)
Gender	Female	105 (82.7%)
	Male	22 (17.3%)
Nationality	United Kingdom	77 (60.6%)
	Not available	50 (39.4%)
Religion	Christian	33 (26.0%)
	Muslim	7 (5.5%)
	Hindu	1 (0.8%)
	Buddhist	1 (0.8%)
	No religion	83 (65.4%)
	Other	1 (0.8%)
	Not available	1 (0.8%)
Ethnicity	Asian	2 (1.6%)
	Indian	1 (0.8%)
	Bangladesh	2 (1.6%)
	Pakistani	2 (1.6%)
	White & Asian	1 (0.8%)
	White & Caribbean	1 (0.8%)
	White British	100 (78.7%)
	Other background	11 (8.7%)
Not available	7 (5.5%)	
Health & Wellbeing		
Suffer from any long-term conditions	Yes	36 (28.3%)
	No	83 (65.4%)
	Prefer not to say	1 (0.8%)
	Not available	7 (5.5%)
Suffer from any disabilities	Yes	5 (3.9%)
	No	113 (89.0%)
	Prefer not to say	2 (1.6%)
	Not available	7 (5.5%)
Taking medication for any mental health condition	Yes	20 (15.7%)
	No	100 (78.8%)
	Not available	7 (5.5%)
Taking medication for any physical condition	Yes	32 (25.2%)
	No	86 (67.7%)
	Prefer not to say	2 (1.6%)
	Not available	7 (5.5%)

Mental health rating since the pandemic	Much better	2 (1.6%)
	Somewhat better	9 (7.1%)
	About the same	45 (35.4%)
	Somewhat worse	54 (42.5%)
	Much worse	9 (7.1%)
	Not available	8 (6.3%)
Physical health rating since the pandemic began	Much better	3 (2.4%)
	Somewhat better	13 (10.2%)
	About the same	58 (45.7%)
	Somewhat worse	39 (30.7%)
	Much worse	6 (4.7%)
	Not available	8 (6.3%)
Test positive for COVID-19 in the past 12 months	Yes	12 (9.4%)
	No	107 (78.7%)
	Not available	8 (6.3%)
Demographics of Quality Assurance Participants (N = 8)		
Variables		N (%)
	25-34	2 (25.0%)
	35-44	2 (25.0%)
	45-54	3 (37.5%)
	55-64	1 (12.5%)
	Gender	Female
	Male	2 (25.0%)
Nationality	United Kingdom	7 (87.5%)
	Not available	1 (12.5%)
Religion	Christian	3 (37.5%)
	No religion	5 (62.5%)
Ethnicity	White British	8 (100.0%)
Health & Wellbeing		
Suffer from any long-term conditions	Yes	2 (25.0%)
	No	6 (75.0%)
Suffer from any disabilities	No	8 (100.0%)
Taking medication for any mental health condition	Yes	1 (12.5%)
	No	7 (87.5%)
Taking medication for any physical condition	Yes	2 (25.0%)
	No	6 (75.5%)
Mental health rating since the pandemic	Somewhat better	1 (12.5%)
	About the same	3 (37.5%)
	Somewhat worse	2 (25.0%)
	Much worse	2 (25.0%)
Physical health rating since the pandemic began	Somewhat better	2 (25.5%)
	About the same	5 (62.5%)
	Somewhat worse	1 (12.5%)
Test positive for COVID-19 in the past 12 months	No	8 (100.0%)




Figure 1: 485 staff members completed the questionnaire flow diagram.

Age

Of 485 respondents, more than half (50.7%) were aged between 35-54 years. In the sample, 2.3% were young adults aged between 18-24 years. Cognitive impairment, one of the four dimensions measured by BAT-12, showed significant differences between age groups. People aged between 18-24 and 35-54 years scored higher compared to other groups. The young adult group scored the highest scores for cognitive impairment, depression, and daily discrimination. The elderly group, aged over 65 years of age had the highest scores for heritage, mainstream, and GSE and the lowest score for everyday discrimination. People aged 45-54 years had the highest anxiety with a score of 11 or over (proportion of 45.1%), while people aged 25-34 years had the lowest anxiety proportion of 39.6%. Table 3 displays the anxiety proportion for people aged 18-24, 25-34, 35- 44, 45-54, 55-64, 65 years and over were 40.0%, 39.6%, 40.0%, 45.1%, 44.4%, and 43.8%, respectively. However, the p-value (0.8092) indicated the anxiety level was independent to age

Table 3: Contingency table of anxiety level, age and gender.

Anxiety Level		Abnormal	Borderline abnormal	Normal	Total
Age	18-24	2	3	0	5
	25-34	21	27	5	53
	35-44	34	37	14	85
	45-54	37	31	14	82
	55-64	20	17	8	45
	65 and over	7	5	4	16
P-value of Chi-Square Test: .8092					
Gender	Male	9	29	10	48
	Female	110	92	35	237
	P-value of Chi-Square Test: .001808*				

Note: 0-7 = Normal, 8-10 = Borderline abnormal (borderline case), 11-21 = Abnormal (case)

statistically.

Gender

Approximately 73.4% of the participants were female and 15.5% were male. Anxiety level was measured by anxiety score, which is the summation of the odds items within the HADS questionnaire. Male participants had a lower averaged anxiety score of 9.2 in comparison to female, 10.4 as shown in Table 4. Of the total 356 female respondents, 237 completed the anxiety questionnaire, thus there was a 33.4% of missingness. Of these 237 women, 110 (46.4%) had an anxiety score of 11 or higher and, 92 (38.8%) reported an anxiety score of 8 to 10. In comparison, of the total 75 male respondents, 48 completed anxiety questionnaires. Of these 48 participants, 9 (18.8%) had an anxiety score of 11 or higher and, 29 (60.4%) had a score of 8-10. The Chi-square test indicated a p-value of 0.001808 suggesting levels of anxiety appears to be similar across the genders (Table 3).

Table 4 also shows men scored significantly lower than women on the dimension of exhaustion (7.8 and 8.7, respectively). Women appear to be less influenced by mainstream and heritage cultures in comparison to men as per the low scores observed from the VIA questionnaire (Table 4).

Table 4: The prevalence of burnout (BAT-12), anxiety and depression (HADS), everyday discrimination, insomnia (ISI) and wellbeing using emotion, optimism and work satisfaction (GSE) among genders and age groups.

Variable	N	BAT-12				HADS		Everyday discrimination	ISI	GSE	VIA	
		Exhaustion	Mental distance	Cognitive impairment	Emotional impairment	Anxiety	Depression				Heritage	Mainstream
Gender												
Female	356	8.7 (2.7)	7.3 (2.9)	8.1 (2.4)	5.5 (2.4)	10.4 (2.6)	8.4 (1.7)	0.8 (0.7)	8.1 (5.8)	3.0 (0.5)	6.44 (1.47)	6.60 (1.44)
Male	75	7.8 (2.7)	7.5 (2.6)	7.9 (2.8)	5.2 (2.1)	9.2 (2.5)	8.4 (1.5)	0.8 (0.6)	6.7 (6.1)	3.1 (0.4)	5.99 (1.46)	6.20 (1.56)
p-values		0.041*	0.607	0.667	0.445	0.002*	0.986	0.965	0.149	0.548	0.060*	0.092*
Age												
18 - 24	11	10.2 (4.3)	7.7 (3.3)	8.3 (3.3)	5.7 (2.4)	10.4 (2.7)	9.5 (2.9)	0.9 (0.7)	10.2 (8.1)	2.8 (0.6)	6.21 (1.05)	6.09 (1.58)
25 - 34	90	8.7 (2.8)	7.2 (2.8)	7.7 (2.5)	5.4 (2.5)	9.8 (2.4)	8.2 (1.6)	0.7 (0.7)	7.7 (6.6)	3.1 (0.4)	6.38 (1.49)	6.65 (1.27)
35 - 44	131	8.6 (2.7)	7.6 (3.0)	8.6 (2.6)	5.4 (2.4)	9.7 (3.2)	8.1 (1.7)	0.8 (0.7)	6.8 (5.7)	3.0 (0.5)	6.31 (1.46)	6.44 (1.44)
45 - 54	115	8.8 (2.6)	7.8 (2.8)	8.2 (2.5)	5.9 (2.7)	10.4 (2.7)	8.6 (1.6)	0.9 (0.7)	8.6 (5.5)	3.0 (0.5)	6.27 (1.45)	6.41 (1.53)
55 - 64	70	7.8 (2.7)	6.9 (2.8)	7.3 (2.2)	5.0 (2.0)	9.8 (2.4)	8.9 (1.6)	0.6 (0.6)	8.2 (5.6)	3.1 (0.4)	6.38 (1.67)	6.64 (1.54)
> 64	21	8.1 (3.2)	5.7 (2.2)	7.1 (2.4)	5.2 (1.7)	9.7 (3.2)	9.0 (1.6)	0.5 (0.4)	8.6 (6.2)	3.3 (0.4)	7.51 (1.37)	7.80 (1.47)
p-values		0.276	0.147	0.042*	0.521	0.699	0.016*	0.054*	0.376	0.070*	0.213	0.089*
Ethnicity												
White British	340	8.5 (2.6)	7.3 (2.8)	8.2 (2.4)	5.4 (2.3)	10.1 (2.5)	8.5 (1.7)	0.7 (0.6)	7.9 (5.9)	3.0 (0.4)	6.25 (1.50)	6.52 (1.49)
Another ethnicity	67	8.8 (3.0)	7.2 (3.1)	7.8 (2.8)	5.7 (2.8)	10.9 (2.8)	8.2 (1.7)	0.9 (0.8)	8.4 (5.8)	3.0 (0.6)	6.78 (1.30)	6.59 (1.29)
p-values		0.562	0.806	0.403	0.46	0.078*	0.193	0.223	0.638	0.57	0.020*	0.751
Length of service												
Less than 1 year	50	7.7 (2.9)	5.8 -2.3	7.0 (2.5)	4.7 (2.1)	9.7-2.3	8.4 (1.8)	0.7 (0.6)	7.7-6.6	3.1 (0.4)	6.36-1.81	6.39-1.76
1 to 5 years	192	8.7 (2.7)	7.9-2.8	8.2 (2.3)	5.6 (2.5)	10.2 (2.7)	8.4 (1.7)	0.8 (0.7)	7.9-5.9	3.0 (0.4)	6.35-1.36	6.57-1.34
6 to 10 years	105	8.7 (2.7)	7.3 -2.9	8.3 (2.7)	5.6 (2.5)	10.7 (2.7)	8.5 (1.6)	0.8 (0.7)	7.8-5.6	3.1 (0.5)	6.37-1.56	6.52 -1.58
11 to 15 years	47	8.8 (2.9)	7.2 -2.7	8.1 (2.6)	5.3 (2.6)	9.8 -2	8.4 (1.9)	0.7 (0.5)	8.3 -6.2	3.1 (0.6)	6.17 -1.41	6.23-1.42
16 to 20 years	7	9.3 (1.3)	8-1.4	7.8 (2.1)	6.3 (0.6)	12.2 (3.6)	8.6 (0.9)	0.8 (0.2)	6.6-2.9	3.0 (0.2)	7.12-2	7.62-1.43
Over 21 years	10	6.6 (3.8)	3.4-0.9	4.6 (1.8)	4.0 (1.4)	8.8-2.7	9.5 (0.8)	0.4 (0.4)	9.3-6.8	3.0 (0.3)	6.72-1.59	6.76-1.57
p-values		0.329	<0.001*	0.008*	0.363	0.106	0.744	0.69	0.978	0.83	0.852	0.504
Professional groups												
Trial management	127	8.4 (2.5)	7.4-2.8	8.4 (2.8)	5.4 (2.3)	7.9-4.3	4.8 (3.6)	0.8 (0.7)	7.1-5.5	3.1 (0.5)		
Quality assurance	8	9.0 (1.9)	7.1-1.8	8.7 (2.0)	4.4 (1.3)	8.7-4.6	3.5 (4.0)	0.9 (0.6)	10.3 (8.3)	3.0 (0.2)		

Database management	34	8.5 (3.0)	7.2-3	8.3 (2.3)	6.1 (2.7)	8-3.9	5.3 (4.0)	0.7 (0.6)	9.1-6.9	2.8 (0.6)		
Doctor/ Nurse	34	8.8 (3.1)	7.1-2.9	7.7 (2.6)	6.2 (3.0)	8.9-4.2	5.9 (4.3)	0.9 (0.8)	8.5 (5.7)	3.0 (0.3)		
Statistician	29	9.2 (3.1)	7.8-2.8	7.8 (2.5)	5.4 (2.7)	8.6-4.4	6.1 (4.7)	0.5 (0.7)	6.5 (5.2)	3.1 (0.4)		
p-values		0.851	0.965	0.723	0.364	0.82	0.48	0.409	0.368	0.209		

Note. Significant values (with p-value less than 0.1) are marked in red .

Mental Health Assessment

Length of Service

The BAT-12 scores appeared to increase with the length of service as indicated in Table 4. Thus, elevated exposure to exhaustion, mental distance, cognitive, and emotional impairment were observed to be common within this group. The ANOVA test showed statistically significant scores between cognitive impairment and mental distance among different lengths of service groups (less than 1 year, 1 to 5 years, 6 to ten years, 11 to 15 years, 16 to 20 years, over 21 years) with p-values of 0.008 and less than 0.001 respectively. P-values were not significant within the exhaustion and emotional impairment dimensions with 0.329 and 0.363, respectively. A trend analysis indicates the overall exhaustion and emotional impairment levels increased with the length of service ranges from less than a year to 20 years. There appears to be a large variation within the data. We excluded the data for the group of over 21 years since the sample size is rather small and it is treated as an outlier.

Well-being

The pooled data listed in Table 2, indicated 25.8% of respondents suffered from long-term conditions and 3.9% from disabilities. Participants who had an existing mental health condition prior to the pandemic (28.2%), believed their disease did not worsen, thus a lack of a notable change in their wellbeing was reported. Approximately, 10.9% of participants with mental health conditions felt better since the pandemic began. Participants that had no mental health problems before (43.1%) reported that their wellbeing worsened since the pandemic began. In 36.3% of participants, physical health conditions did not change since the beginning of the pandemic began whilst 13.4% of participants felt there were improvements. Approximately 32.8% of participants reported their physical condition worsened since the pandemic began.

Of the trial management participants, 28.3% suffered from long-term conditions which is slightly higher than CTU staff. Clinical trials reported their mental health and physical health conditions worsened since the pandemic began, in comparison to other professional groups with 49.6% and 35.4%, respectively. These participants also had higher use of medications for their mental and physical conditions; 15.7% and 25.2%, respectively, as shown in Table 5. In comparison, the remaining participants had a lower percentage of medication use for mental and physical health with 12.6% and 19.8, respectively. The cognitive impairment level is relatively higher among the clinical trialist group with an average impairment score of 8.40 compared to the rest of study participants (7.93).

Professional group outcomes

Five different professional groups with acceptable sample size (ranging from 8 to 127, mean 46.4) were considered in the analysis (trial management, quality assurance, database management, doctor/nurse, statistician). Statisticians had the highest level of exhaustion, mental distance, and depression whilst quality assurance staff had the highest level of cognitive impairment. Nurses and doctors appeared to have the highest scores for anxiety and emotional impairment. Although, this has clinical significance in relation to the wellbeing of staff, an overall statistical significance could not be determined based on limited professional group sample sizes. The demographic characteristics and their association with burnout, HADS, everyday discrimination, ISI and GSE is indicated in Table 4. Approximately, 28.3% of participants working in trial management suffered from long-term conditions, which is slightly higher than that of the study population (Table 5). On the other hand, a high proportion of clinical trialists felt their mental and physical health had worsened since the pandemic began in comparison to other professional groups, 49.6% and 35.4%, respectively (Table 5).

Table 5: Key characteristics of Trial Management & Quality Assurance participants.

Demographics of Trail Management Participants (N = 127)		
Variables		N (%)
Age	18-24	1 (0.8%)
	25-34	23 (18.1%)
	35-44	46 (36.2%)
	45-54	35 (27.6%)
	55-64	17 (13.4%)
	65 and over	5 (3.9%)
Gender	Female	105 (82.7%)
	Male	22 (17.3%)
Nationality	United Kingdom	77 (60.6%)
	Not available	50 (39.4%)
Religion	Christian	33 (26.0%)
	Muslim	7 (5.5%)
	Hindu	1 (0.8%)
	Buddhist	1 (0.8%)
	No religion	83 (65.4%)
	Other	1 (0.8%)
	Not available	1 (0.8%)
Ethnicity	Asian	2 (1.6%)
	Indian	1 (0.8%)
	Bangladesh	2 (1.6%)
	Pakistani	2 (1.6%)
	White & Asian	1 (0.8%)
	White & Caribbean	1 (0.8%)
	White British	100 (78.7%)
	Other background	11 (8.7%)
Not available	7 (5.5%)	
Health & Wellbeing		
Suffer from any long-term conditions	Yes	36 (28.3%)
	No	83 (65.4%)
	Prefer not to say	1 (0.8%)
	Not available	7 (5.5%)
Suffer from any disabilities	Yes	5 (3.9%)
	No	113 (89.0%)
	Prefer not to say	2 (1.6%)
	Not available	7 (5.5%)
Taking medication for any mental health condition	Yes	20 (15.7%)
	No	100 (78.8%)
	Not available	7 (5.5%)
Taking medication for any physical condition	Yes	32 (25.2%)
	No	86 (67.7%)
	Prefer not to say	2 (1.6%)
	Not available	7 (5.5%)

Mental health rating since the pandemic	Much better	2 (1.6%)
	Somewhat better	9 (7.1%)
	About the same	45 (35.4%)
	Somewhat worse	54 (42.5%)
	Much worse	9 (7.1%)
	Not available	8 (6.3%)
Physical health rating since the pandemic began	Much better	3 (2.4%)
	Somewhat better	13 (10.2%)
	About the same	58 (45.7%)
	Somewhat worse	39 (30.7%)
	Much worse	6 (4.7%)
	Not available	8 (6.3%)
Test positive for COVID-19 in the past 12 months	Yes	12 (9.4%)
	No	107 (78.7%)
	Not available	8 (6.3%)
Demographics of Quality Assurance Participants (N = 8)		
Variables		N (%)
	25-34	2 (25.0%)
	35-44	2 (25.0%)
	45-54	3 (37.5%)
	55-64	1 (12.5%)
Gender	Female	6 (75.0%)
	Male	2 (25.0%)
Nationality	United Kingdom	7 (87.5%)
	Not available	1 (12.5%)
Religion	Christian	3 (37.5%)
	No religion	5 (62.5%)
Ethnicity	White British	8 (100.0%)
Health & Wellbeing		
Suffer from any long-term conditions	Yes	2 (25.0%)
	No	6 (75.0%)
Suffer from any disabilities	No	8 (100.0%)
Taking medication for any mental health condition	Yes	1 (12.5%)
	No	7 (87.5%)
Taking medication for any physical condition	Yes	2 (25.0%)
	No	6 (75.5%)
Mental health rating since the pandemic	Somewhat better	1 (12.5%)
	About the same	3 (37.5%)
	Somewhat worse	2 (25.0%)
	Much worse	2 (25.0%)
Physical health rating since the pandemic began	Somewhat better	2 (25.5%)
	About the same	5 (62.5%)
	Somewhat worse	1 (12.5%)
Test positive for COVID-19 in the past 12 months	No	8 (100.0%)

Ethnicity

In terms of ethnicity and race, 70.1% of the respondents were white British and 13% were of ethnic minorities (African, Asian, Bangladeshi and Indian descent). Ethnic minorities were grouped for the purpose of conducting meaningful analysis to evaluate their mental health outcomes. T-tests showed anxiety levels of White

British participants were significantly lower in comparison to ethnic minorities as indicated in Table 4. Participants from ethnic minority groups believed that the outside world may be more afraid of them ($p = 0.015$) or that people acted like they were more dishonest than White British ($p = 0.054$). Table 6 presents the mean (SD) and item correlations for the ISI scores.

Table 6: Mean (SD), item-total correlations for the ISIS.

Severity	Mean (SD)	Item-total r
Initial (Difficulty falling asleep) sleep onset	0.99 (1.10)	0.5456
Middle (Difficulty staying asleep) sleep maintenance	1.18 (1.12)	0.7461
Terminal (Problem waking up too early)	1.16 (1.19)	0.6095
Satisfaction	1.87 (1.20)	0.7554
Interference	1.08 (1.02)	0.7758
Noticeability	0.90 (1.00)	0.7232
Distress (Worried)	0.70 (0.84)	0.7579
Total	7.88 (5.86)	

Heat-map correlation

Based on the heatmap, heritage and mainstream scores were highly associated with each other based on the spearman correlation score of 0.8. Anxiety level showed a strong correlation with lev-

els of depression, insomnia, exhaustion, emotional impairment, and cognitive impairment where the spearman correlation greater than 0.4. GSE and everyday discrimination showed a correlation with the four dimensions of BAT-12 although the spearman correlation was less than -0.4 and over 0.3, respectively, as illustrated in Figure2.




Figure 2: GSE and everyday discrimination showed a correlation with the four dimensions of BAT-12 although the spearman correlation was less than -0.4 and over 0.3

Linear regression

To investigate whether long term exposure to high level stressful environment has influence staff mental health, anxiety, depression and burn out scores were combined (denoted by y) and plotted

it against the length of service (using the mid-point for each group, denoted by x) in Figure 3. The overall score increased along the length of service. except for the group with over 21years length of employment.




Figure 3: High level stressful environment has influence staff mental health, anxiety, depression and burn out scores were combined and plotted it against the length of service

Item-total correlations of ISI

Means and standard deviations for the ISI and sleep diary measures are reported in Table 7. The ISI average total score was 7.88 (SD 5.86). The internal consistency of the ISI was estimated with a

Cronbach alpha coefficient and by the item-total correlations. The internal consistency, (i.e., degree of consistency or homogeneity of the items within a scale) of the ISI was 0.74. The item-total correlations varied from a low of 0.55 (initial) to a high of 0.78 (interference) with an average of 0.70.

Table 7: Summary Table of Outcome Measures.

Scale information			
Vancouver Index of Acculturation (VIA)			
Heritage score	6.36 / 9 (1.48)	Mainstream score	6.53 / 9 (1.47)
Hospital Anxiety and Depression Scale (HADS)			
Anxiety score	10.24 / 21 (2.60)	Depression score	8.46 / 21 (1.69)
Insomnia Severity Index (ISI)			
Insomnia score	7.88 / 28 (5.86)		
Pandemic Stress Index (PSI)			
Behavioral experiences during COVID-19	No changes to my life or behaviour		3 (0.62%)
	Practicing social distancing		278 (57.32%)
	Isolating or quarantine yourself		154 (31.75%)
	Caring for someone at home		43 (8.87%)
	Working from home		268 (55.26%)
	Not working		8 (1.65%)
	A change in use of healthcare services		107 (22.06%)
	Following media coverage related to COVID-19		233 (48.04%)
	Changing travel plans		207 (42.68%)

Impact of COVID-19 on day-to-day life	Not at all	4 (0.82%)	
	A little	50 (10.31%)	
	Much	66 (13.61%)	
	Very Much	93 (19.18%)	
	Extremely	65 (13.40%)	
Physical and mental experiences during COVID-19	Being diagnosed with COVID-19	40 (8.25%)	
	Fear of getting COVID-19	135 (27.84%)	
	Fear of giving COVID-19 to someone else	185 (38.14%)	
	Worrying about friends, family, partners, etc.	236 (48.66%)	
	Stigma or discrimination from other people	23 (4.74%)	
	Personal financial loss	41 (8.45%)	
	Frustration or boredom	160 (32.99%)	
	Not having enough basic supplies	24 (4.95%)	
	More anxiety	151 (31.13%)	
	More depression	70 (14.43%)	
	More sleep, less sleep, or other changes to your normal sleep pattern	115 (23.71%)	
	Increased alcohol or other substance use	79 (16.29%)	
	A change in sexual activity	43 (8.87%)	
	Loneliness	106 (21.86%)	
	Confusion about what COVID-19 is, how to prevent it, or why social distancing/isolation/quarantines are needed	24 (4.95%)	
	Feeling that I was contributing to the greater good by preventing myself or others from getting COVID-19	167 (34.43%)	
	Getting emotional or social support from family, friends, partners, a counsellor, or someone else	89 (18.35%)	
Getting financial support from family, friends, partners, an organisation, or someone else	10 (2.06%)		
Other difficulties or challenges	49 (10.10%)		
General Self Efficacy Scale (GSE)			
Average self efficacy score	3.04 / 4 (0.46)		
Burnout Assessment Tool-12 (BAT-12)			
Exhaustion score	8.57 / 15 (2.75)	Cognitive impairment score	8.05 / 15 (2.51)
Mental distance score	7.33 / 15 (2.86)	Emotional impairment score	5.46 / 15 (2.42)
The Everyday Discrimination Scale (EDS)			
Average discrimination score	0.77 / 5 (0.65)		

Geographical

Of the 485 respondents, 137 disclosed their longitude and latitude, accounting for about 59% of the sample. The majority of respondents were from England, mostly concentrated in the central and southern parts of England, including Southampton, Bristol, London, Oxford, and Birmingham. Scotland had the second largest number of respondents primarily from Edinburgh, Glasgow, and Dundee.

Qualitative

For the qualitative part of the study, 6 participants (4 women and 2 men) consented and completed interviews (Supplementary

Document 1). Their interview durations ranged from 26 to 54 minutes. Respondents included a senior statistician, research nurses and trials managers. Participants rated their work-related stress levels between 3 and 6. Two participants felt things had worsened since the beginning of the COVID-19 pandemic, whilst one reported there had been improvements and another claimed things had returned to pre-COVID-19 levels. There was a general sense that the job came with periods of high pressure that exacerbated stress levels, however this was unrelated to COVID-19. Participants reported pre-COVID-19 related daily work issues associated with clinical trials they were working on, office environment, and the commute. Differing views were reported on the perceived effectiveness of

open plan offices in terms of noise, distractions and challenges associated with some processes required for clinical trials management. There were also tasks that could no longer be completed as before due to changes to workforce availability. Research nurses re-deployed to support COVID-19 patients in frontline services meant recruitment activities to most clinical studies were paused. Others transitioned to an 'on-line' or 'telephone' mode of delivery of services where possible.

Some of the emergent themes are illustrated by verbatim quotes below:

'now you have a bit more spare time and are not being pestered by colleagues all of the time on the office, it helps' [P, 002]; ...

'things went very scary, very high for every area of life for everybody

This is how we operate now, there's certainly an acceptance so not very high but the bar is set a lot lower now' [P, 003].

At the height of COVID, there was an overwhelming sense of things being beyond individual control as highlighted by these quotes:

'it was awful..... in terms of your day, your day wasn't your own ... the adrenalin kicked in because everyone was going into survival mode ...' [P 003].

Similarly, 'mostly things that are out of my control things that are out of my hand that are stressful ... such as recruitment levels, trying to get that sorted' [P 001] '...

the whole situation was intensely stressful' [P 006].

Work-life balance. For some home-working and managing childcare was challenging during this period, as expressed by this respondent: '

I was home-schooling on my own, trying to work at home. That was the most stressful point I think because it's virtually impossible with a five year-old to home school and work at the same time, so I was working evenings and weekends and it was just constant and then, because we were in lockdown we didn't see anyone, we didn't go anywhere, we were totally isolated.' [P 006].

I wouldn't say it was all plain sailing because that's not the case [P 003]'... nobody had an escape plan, nobody had down time but 10, 11 o'clock at night emailing isn't ideal' [P 003]. '...

I respond to emails any time e.g., at 11pm, I can give a quick answer and it's done. It's good and bad. I'm quite responsive with people, I'm not a stickler with hours. [P, 004].

'There is an expectation to work more from one person who wants to have meetings at 6-7 in the evening. As such as lockdown was done, I didn't want to do that anymore' [P, 002].

Information technology (IT) and remote/hybrid working. 'I used to have two meetings a week on zoom and there was a time when there were 7 (meetings) a day' [P, 003].

'You bounce from meeting to meeting rather than doing it physically' [P, 001]. There were positives, however with some respond-

ents saying: 'I do think your true self comes out, everyone's much more relaxed in a zoom environment than we were before, because you have to be. That's the norm and it's taken the pressure off.' [P, 003].'

...being able to jump into a meeting easily, no distractions ..' [P, 002]'

'The university have gone down a blended approach ... giving people the flexibility People being more responsible for their own workloads ... getting more out of people' [P , 003].

Changes to the workplace

'It was quite hard because it's a big open plan office which is why we're not sort of back in the office yet because they're trying to work out ventilation and hot-desking and stuff..... a key part of what helps me do my work is a big pair of noise-cancelling headphones because it's too loud and I get distracted really easily' [P, 004].

'Technically, we're back but not everyone is yet. All the desks have moved. Having to travel again is weird. There are no face-to-face meetings, just getting back to being back close to people on the commute again'. [P, 005].

There were also positive experiences, however 'I didn't realise till I started to go back in just how refreshing it is to have, like, even a laugh with someone in your office. Just to have that two minute's [P, 005].

Communication

'The biggest problem was in the communication We realised no-one's coming back full-time and had to adapt to different ways of working and communicating' [P, 005].

'In the early days, the doors were just closed. That was it, just closed' [P, 003].

Administration

'Basically, you've got to apply to work, to use anywhere and get approval, use the clinic rooms for studies' [P, 006].

Staff redeployment, recruitment, and shortages:

'We were briefly redeployed again, which was very stressful. Having to go to a new area and work with strangers on something I really didn't know a lot about, which was stressful' [P, 006].

'The inability to recruit other members and roles as they might be attracted to other sectors ... no lack of money, just lack of staff' [P, 002].

Overall, there was a sense of uncertainty despite the pandemic status in the UK changing. There were mixed views on the desirability of office working and returning to a pre-COVID-19 working style.

Discussion

The main objective of this research study was to determine the mental health impact on clinical trial staff due to challenges faced whilst delivering clinical research throughout the COVID-19 pan-

demographic. 485 respondents were eligible to participate in the study and completed the questionnaire. We reported the demographic characteristics of all samples and conducted a quantitative analysis on respondents in terms of age, gender, length of service, well-being, professional group outcomes and other indicators. The ANOVA test showed statistically significant scores between cognitive impairment and mental distance among different lengths of service groups. A trend analysis also indicates the overall exhaustion and emotional impairment levels increased with the length of service ranges from less than a year to 20 years. 25.8% of respondents suffered from long-term conditions and 3.9% from disabilities. 43.1% of the participants that had no mental health problems before reported that their wellbeing worsened since the pandemic began. Approximately 32.8% of participants reported their physical condition worsened since the pandemic began. The BAT-12 measured cognitive impairments and results found that the young adult group presented with the highest levels of cognitive impairment and daily discrimination. The HADS questionnaire was used to measure anxiety and depression. On average, male participants has a lower anxiety score than females, with 85.2% of females reporting an anxiety score of 8 or higher. Men seemed to be highly influenced by mainstream and heritage cultures in comparison to females, as assessed by the VIA.

Of the trial management participants, 28.3% suffered from long-term conditions which is slightly higher than CTU staff. Clinical trials reported their mental health and physical health conditions worsened since the pandemic began, in comparison to other professional groups with 49.6% and 35.4%, respectively. Participants from ethnic minority groups believed that the outside world may be more afraid of them ($p = 0.015$) or that people acted like they were more dishonest than White British ($p = 0.054$). A linear regression model indicates that the overall score of BAT12 increased along the length of service. Based on the collective findings, the negative mental health impact on the CTU workforce due to the COVID-19 pandemic is evident. Experiences of stress and burnout were of varying degrees when comparing those with and without a pre-existing mental illness or a physical condition. Previous studies found that the majority of healthcare workers recruited experienced some form of psychological distress throughout the pandemic [10]. Increases in levels of stress, anxiety, depression and insomnia were experienced by all healthcare staff [11]. Future clinical reviews would be beneficial for the CTU workforce. Moreover, COVID-19 has demonstrated the importance of diversity and the disproportionate impact that minority populations endured [12]. Based on the study results, there appears to be under-representation of ethnic minorities in CTU staff despite around 45% of the NHS workforce constituting of ethnic minority staff [16]. Studies have found an ethnic bias more prominently present throughout the COVID-19 pandemic which has disadvantaged minority groups [12-14]. Adequate representation could have facilitated more meaningful conclusions about the impact of COVID-19 on the mental health of CTU staff from minority ethnic groups within this study. A better understanding would help to improve the provision for minority ethnic staff in other NHS professional groups.

The mental health impact identified may result in increased sickness absences. This would also have a negative impact on performance and efficiency. Whilst this study cannot determine the precise medium and long-term effects of increased sickness absences at an individual and organisational level, a negative impact can be determined if the overall wellbeing remains the same. Findings from previous studies have shown that sickness absence was significantly higher throughout and post-pandemic [15]. It appears, there is significant variability in experiences and opinions around lived experience professionally and personally during the pandemic. Participants reflected powerful insights into the impact of COVID-19 whilst working to deliver COVID-19 research in a CTU environment. Similar to these findings, studies have revealed that healthcare professionals report mild anxiety and depression in higher proportions compared to the public [16-18]. A scoping review looking at the effects of COVID-19 on healthcare staff globally found that employees from all domains of healthcare experienced increased levels of depression, anxiety, and stress [19].

Limitations

Enrolment of participants could have been increased with less pressure on the CTU workforce. Furthermore, there were numerous observational and vaccine-related interventional studies during this period that could have resulted in this study competing with other portfolio studies for staff recruitment and participation. There is already a lack of representation for ethnic minorities within clinical research and the same issue seems to have arisen within this study. As minority ethnic groups were the most impacted by the pandemic, it would have been insightful to focus on recruiting higher proportions of CTU staff from these groups. There were considerable challenges to increase participants for the qualitative component of the study. Longitudinal data collection could be a useful step as it would enable continual assessment of findings to aid CTU workforce and employers make quality improvements.

Conclusion

This study indicates the substantial personal impact the CTU workforce have encountered during the pandemic. Viability of sustainable clinical trial conduct is based on multi-professional involvement in CTU settings thus, it would be in the interest of all healthcare professionals to improve the support systems available to better manage working conditions especially as part of pandemic preparedness. Recommendations to inform 'Future Preparedness' in supporting the CTU workforce in delivering pandemic and non-pandemic research include ensuring continuity and clarity of communication via different media, providing opportunities for flexibility in working hours, within reasonable constraints and ensuring staff are not pressured into work during times they would not usually do so. Additionally, it would be appropriate to include opportunities for collaborative problem-solving via different media as per the needs of individual team members and maintaining consistency, where possible, in frequency and content of contact so that staff feel supported in different aspects of their working roles. Finally, contingency planning of supplies of necessary equipment for effective home working should be considered in line with all rel-

evant health and safety legislation to ensure the wellbeing of CTU workforce as they lead in the delivery of cutting edge innovative clinical trials that will be tomorrow's interventions.

Declarations

Funding

This work is funded by the NIHR Senior Investigator Award to Professor Lucy Yardley.

Conflicts of Interest

PP has received research grant from Novo Nordisk, and other, educational from Queen Mary University of London, other from John Wiley & Sons, other from Otsuka, outside the submitted work. SR reports other from Janssen, Lundbeck and Otsuka outside the submitted work. All other authors report no conflict of interest. The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or the Academic institutions.

Availability of Data and Material

The authors will consider sharing the dataset gathered upon receipt of reasonable requests.

Code Availability

The authors will consider sharing the dataset gathered upon receipt of reasonable requests.

Author Contributions

GD and PP developed the study protocol and embedded this within the EPIC project's work-package 3. The Chief Investigator of this study is PP and Principal Investigator GD. GD, JT and JQS designed and completed the statistical analysis. The qualitative analysis was completed by KBK, PP and GD. All authors critically appraised and commented on previous versions of the manuscript. All authors read and approved the final manuscript. All authors have read and agreed to the published version of the manuscript."

Ethics Approval

HRA REC approval (21/HRA/2348) was obtained prior to the study initiation.

Consent to Participate

All participants consented to take part in this study.

Consent for Publication

All authors consented to publish this manuscript.

Acknowledgements

The authors acknowledge support from Southern Health NHS Foundation Trust. The authors thank Professor Lucy Yardley for her support with the SI Funding.

References


- (2020) WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 (Internet) World Health Organization.
- (2022) Legislation Gov UK (Internet) UK Government Available from: Coronavirus Legislation.
- Mitchell EJ, Ahmed K, Breeman S, Cotton S, Constable L, et al. (2020) It is unprecedented: trial management during the COVID-19 pandemic and beyond. *Trials* 21(1): 1-7.
- Bhatt A (2020) Clinical trials during the COVID-19 pandemic: Challenges of putting scientific and ethical principles into practice *Perspectives in Clinical Research* 11(2): 59.
- (2022) Indeed Available from: Clinical Trials Jobs Indeed.com.
- (2021) NIHR covid Studies National Institute for Health and Care Research.
- Thornton J (2020) Clinical trials suspended in UK to prioritise covid-19 studies and free up staff. *BMJ* 368: m1172.
- Bitencourt MR, Alarcão AC, Silva LL, Dutra AD, Caruzzo NM, et al. (2021) Predictors of violence against health professionals during the COVID-19 pandemic in Brazil: A cross-sectional study *PLoS One* 16(6): e0253398.
- Jesuthasan J, Powell RA, Burmester V, Nicholls D (2021) 'We weren't checked in on, nobody spoke to us': an exploratory qualitative analysis of two focus groups on the concerns of ethnic minority NHS staff during COVID-19 *BMJ Open* 11(12): e053396.
- Tam CW, Pang EP, Lam LC, Chiu HF (2004) Severe acute respiratory syndrome (SARS) in Hong Kong in 2003: stress and psychological impact among frontline healthcare workers *Psychological medicine* 34(7): 1197-204.
- Lai J, Ma S, Wang Y, Cai Z, Hu J (2020) Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019 *JAMA network open* 3(3): e203976.
- Phiri P, Delanerolle G, Al-Sudani A, Rathod S (2021) COVID-19 and black, Asian, and minority ethnic communities: a complex relationship without just cause *JMIR public health and surveillance* 7(2): e22581.
- Phiri P, Rathod S, Elliot K, Delanerolle G (2020) The Impact of COVID-19 on the mental wellbeing of healthcare staff *EJPMR* 7(8): 66-71.
- Delanerolle G, Rathod S, Elliot K, Ramakrishnan R, Thayanandan T, et al. (2021) Rapid commentary: Ethical implications for clinical trialists and patients associated with COVID-19 research *World Journal of Psychiatry* 11(3) DOI: 10.5498/wjp.v11.i3.0000.
- (2015) The Report Freedom to Speak Up.
- Khorasane R, Grundy T, Isted A, Breeze R (2021) The effects of COVID-19 on sickness of medical staff across departments: A single centre experience *Clinical Medicine* 21(2): e150.
- Rathod S, Pallikadavath S, Young AH, Graves L, Rahman MM, (2020) Psychological impact of COVID-19 pandemic: Protocol and results of first three weeks from an international cross-section survey-focus on health professionals *Journal of affective disorders reports* 1: 100005.
- Hall H (2020) The effect of the COVID-19 pandemic on healthcare workers' mental health *Jaapa* 33(7): 45-8.
- Shreffler J, Petrey J, Huecker M (2020) The impact of COVID-19 on healthcare worker wellness: a scoping review *Western Journal of Emergency Medicine* 21(5): 1059.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here: [Submit Article](#)

DOI: [10.32474/LOJMS.2023.06.000244](https://doi.org/10.32474/LOJMS.2023.06.000244)



Lupine Online Journal of Medical Sciences

Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles